The Pouchitis drugs in development market research report provides comprehensive information on the therapeutics under development for Pouchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pouchitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pouchitis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Pouchitis by ten companies/universities/institutes. The top development phase for Pouchitis is phase ii with five drugs in that stage. The Pouchitis pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pouchitis pipeline products market are: Cosmo Pharmaceuticals, Johnson & Johnson and Novo Nordisk.
The key targets in the Pouchitis pipeline products market include DNA, Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4), and Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7).
The key mechanisms of action in the Pouchitis pipeline product include DNA Synthesis Inhibitor with two drugs in Phase II. The Pouchitis pipeline products include six routes of administration with the top ROA being Oral and five key molecule types in the Pouchitis pipeline products market including Small Molecule, and Biologic.
Pouchitis overview
Pouchitis is an inflammatory condition that occurs as a complication in patients who underwent restorative proctocolectomy or also defined as a condition resulting after the pouch surgery. Genetic mutations may also result in this condition. Increased stool frequency, strong urge for bowel movement, abdominal pain, and presented with fever, dehydration, malnutrition. There is no specific treatment for pouchitis generally off-label drugs used for treating IBD are considered for the management of this condition. Probiotics and antibiotics as a prophylaxis to prevent secondary infections.
For a complete picture of Pouchitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
